FIELD: chemistry.
SUBSTANCE: present invention relates to compounds of formula I and their pharmaceutically acceptable salts and esters. The disclosed compounds have inhibitory effect on cyclin-dependant kinase. In formula I R1 denotes , R3 is selected from a group consisting of H, CO2R6, C(O)R6, SO2R6 and SO2NR5R6, R5 and R6 are each independently selected from a group which includes H and (lower)alkyl, R2 is phenyl which contains one, two or three substitutes independently selected from a group which includes halogen or -O-(lower)alkyl.
EFFECT: preparation of a pharmaceutical composition which contains an effective amount of a formula I compound as an active ingredient.
6 cl, 1 tbl, 22 ex
Title | Year | Author | Number |
---|---|---|---|
PYRAZOLEPYRIMIDINES | 2005 |
|
RU2412186C2 |
NOVEL DERIVATIVES OF 2,6-DIAMINOPYRIDIN-3-ONE | 2005 |
|
RU2385866C2 |
DIAMINOTHIAZOLES POSSESSING PROPERTY OF CYCLIN-DEPENDENT KINASE 4 INHIBITOR | 2003 |
|
RU2311414C2 |
COMPOUNDS | 2008 |
|
RU2461559C2 |
QUINAZOLINYLMETHYLENETRIAZOLINONES AS CDK-1 INHIBITORS | 2005 |
|
RU2405782C2 |
NOVEL AZAINDOLE THIAZOLINONES AS ANTI-CANCER AGENTS | 2005 |
|
RU2391342C2 |
BENZIMIDAZOLE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND USE | 2017 |
|
RU2779534C2 |
1, 5-NAPHTHYRIDINAZOLIDINONES EXHIBITING CDK1 ANTIPROLIFERATIVE ACTIVITY | 2005 |
|
RU2405781C2 |
ARYLCARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | 2003 |
|
RU2340605C2 |
JAK INHIBITORS | 2010 |
|
RU2538204C2 |
Authors
Dates
2010-07-27—Published
2005-07-07—Filed